Page 88 - Read Online

Page 12 of 13 Farrell et al. Hepatoma Res 2020;6:18 I http://dx.doi.org/10.20517/2394-5079.2019.019

for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver
disease. J Hepatol 2016;64:1388-402.
10. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, et al. The diagnosis and management of nonalcoholic fatty liver disease:
practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328-57.
11. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic
steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology
2011;140:124-31.
12. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006;43:S99-112.
13. Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in
NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547-54.
14. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, et al. Liver fibrosis, but no other histologic features, is associated with
long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015;149:389-97.e10.
15. Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease:
systematic review and meta-analysis. Hepatology 2017;65:1557-65.
16. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, et al. Fibrosis progression in nonalcoholic fatty liver vs. nonalcoholic steatohepatitis:
a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13:643-54.e1-9.
17. Loomba R, Adams LA. The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH.
Hepatology 2019;70:1885-88.
18. Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, et al. The natural history of advanced fibrosis due to nonalcoholic
steatohepatitis: data from the simtuzumab Trials. Hepatology 2019;70:1913-27.
19. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al.; Global Burden of Disease Collaboration. Global, regional, and
national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups,
1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 2017;3:524-48.
20. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and
mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
21. Wong MC, Jiang JY, Goggins WB, Liang M, Fang Y, et al. International incidence and mortality trends of liver cancer: a global profile.
Sci Rep 2017;7:45846.
22. Baecker A, Liu X, La Vecchia C, Zhang ZF. Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors. Eur
J Cancer Prev 2018;27:205-12.
23. Kim D, Li AA, Perumpail BJ, Gadiparthi C, Kim W, et al. Changing trends in etiology-based and ethnicity-based annual mortality rates
of cirrhosis and hepatocellular carcinoma in the United States. Hepatology 2019;69:1064-74.
24. El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology
2014;60:1767-75.
25. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from
1975 to 2005. J Clin Oncol 2009;27:1485-91.
26. Wallace MC, Preen DB, Short MW, Adams LA, Jeffrey GP. Hepatocellular carcinoma in Australia 1982-2014: increasing incidence and
improving survival. Liver Int 2019;39:522-30.
27. Australian Institute of Health and Welfare. Cancer in Australia 2019. Available from: https://www.aihw.gov.au/reports/cancer/cancer-in-
australia-2019/formats [Last accessed on 12 Mar 2020]
28. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013;10:553-62.
29. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013;10:686-90.
30. Yang B, Liu JB, So SK, Han SS, Wang SS, et al. Disparities in hepatocellular carcinoma incidence by race/ethnicity and geographic area
in California: implications for prevention. Cancer 2018;124:3551-59.
31. Pham C, Fong TL, Zhang J, Liu L. Striking racial/ethnic disparities in liver cancer incidence rates and temporal trends in California,
1988-2012. J Natl Cancer Inst 2018;110:1259-69.
32. Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, et al. Risk of hepatocellular cancer in patients with non-alcoholic
fatty liver disease. Gastroenterology 2018;155:1828-37.e2.
33. Danford CJ, Yao ZM, Jiang ZG. Non-alcoholic fatty liver disease: a narrative review of genetics. J Biomed Res 2018;32:389-400.
34. Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a
multidisciplinary team. J Hepatol 2014;60:110-7.
35. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and
non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274-85.
36. Sanyal A, Poklepovic A, Moyneur E, Barghout V. Population-based risk factors and resource utilization for HCC: US perspective. Curr
Med Res Opin 2010;26:2183-91.
37. Mittal S, Sada YH, El-Serag HB, Kanwal F, Duan Z, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular
carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol 2015;13:594-601.e1.
38. Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients
with hepatocellular carcinoma in the U.S. Hepatology 2014;59:2188-95.
39. Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, et al. Global perspectives on nonalcoholic fatty liver disease and
nonalcoholic steatohepatitis. Hepatology 2019;69:2672-82.
40. Belli LS, Perricone G, Adam R, Cortesi PA, Strazzabosco M, et al. Impact of DAAs on liver transplantation: Major effects on the
evolution of indications and results. An ELITA study based on the ELTR registry. J Hepatol 2018;69:810-17.